Latest Breaking News On - Neurology of the french academy sciences - Page 1 : comparemela.com

Aelis Farma Announces its 2023 Financial Calendar

Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders

AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which

Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award

Pier Vincenzo Piazza has won in the "Scale-Up" category for France's Nouvelle Aquitaine region Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage

Aelis Farma: Availability of the 2022 Half-year Financial Report

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today

Aelis Farma reports 2022 half-year financial results and confirms its development objectives

H1 2022 marked by the start of recruitment for the phase 2b study with AEF0117 for the treatment of cannabis addiction Solid cash position at €39.8 million as of June 30, 2022, including the